For decades, a diagnosis of astrocytoma — a brain tumor that strikes disproportionately among younger adults — carried with it a grim arithmetic: surgery, then a waiting game before radiation and chemotherapy exacted their own cognitive toll. In August 2024, the FDA approved vorasidenib, the first genuinely new treatment for this cancer in a generation, offering patients a daily pill that targets the tumor's specific molecular pathway while sparing the rest of the body. The stories of two patients at the University of Rochester's Wilmot Cancer Institute illuminate what this shift means not mer
First new astrocytoma treatment in decades offers hope for brain cancer patients
Patients with astrocytoma, including younger adults, previously faced cognitive decline from radiation therapy affecting memory, emotions, work, and relationships; vorasidenib offers relief from these long-term harms.
Whatever we can do to delay or avoid radiation therapy to the brain, especially in younger people, is a good thing.
Mark
Why does it matter that this is the first new astrocytoma treatment in decades? Aren't there other brain cancer drugs?
Mimi
Brain cancer is rare enough that drug development moves slowly. Most treatments were developed in the 1990s. When you're treating a disease that affects so few people, it's hard to gather the data you need to prove a drug works and get FDA approval.
Mark
So vorasidenib is just one drug. What makes it different from what came before?
Mimi
It's a daily pill that targets the specific pathway where this cancer grows, and it has almost no side effects. The old standard was chemotherapy and radiation, which work but cause real damage over time—memory problems, emotional changes, cognitive decline that affects your whole life.
Mark
The article mentions a 27-county region with "neuro-oncology deserts." What does that mean?
Mimi
It means most doctors in those areas almost never see brain cancer. A typical oncologist might see two hundred new patients a year and encounter brain cancer in one of them. They're not up to date on the latest treatments. Patients in rural areas often don't know what options exist.
Mark
How does publishing national guidelines help that problem?
Mimi
When a community doctor has a brain cancer patient in front of them, they can look at the guidelines and quickly see what the current best practices are. It's a way to democratize knowledge that would otherwise stay concentrated in major cancer centers.
Mark
Art Sullivan ran a marathon four months after brain surgery. Is that typical?
Mimi
He was a longtime endurance athlete, so he was exceptionally fit going in. But the point isn't that everyone will do that. The point is that he had the physical capacity to recover, and emotionally, having a treatment option that didn't involve radiation helped him move forward.
Mark
You said vorasidenib isn't a cure. So what is it?
Mimi
It's a big step forward. It delays the need for chemotherapy and radiation, sometimes for years. For someone who might live twenty years with this cancer, that delay matters enormously. It means more years of normal life, normal cognition, normal relationships.
Le Pouls
- Astrocytoma has long been a slow-moving but relentless adversary, with most available treatments dating to the 1990s and radiation's cognitive side effects — memory loss, emotional disruption, damaged relationships — representing a second injury layered onto the first.
- A 331-patient clinical trial demonstrated that vorasidenib significantly delays cancer recurrence and postpones the need for toxic traditional therapies, a breakthrough that neuro-oncologists describe as a fundamental shift toward targeted, molecularly precise medicine.
- Access remains dangerously uneven: neuro-oncology deserts stretch across rural regions where community physicians may encounter brain cancer only once a year, leaving patients without knowledge of options that could transform their prognosis.
- Updated national guidelines published in the Journal of Clinical Oncology and a second newly approved brain tumor drug, dordaviprone, signal that the field is finally accelerating — with CAR T-cell therapy for solid tumors and radiation-protective research waiting in the pipeline.
For decades, a diagnosis of astrocytoma — a brain tumor that strikes disproportionately among younger adults — carried with it a grim arithmetic: surgery, then a waiting game before radiation and chemotherapy exacted their own cognitive toll. In August 2024, the FDA approved vorasidenib, the first genuinely new treatment for this cancer in a generation, offering patients a daily pill that targets the tumor's specific molecular pathway while sparing the rest of the body. The stories of two patients at the University of Rochester's Wilmot Cancer Institute illuminate what this shift means not merely in clinical terms, but in the texture of lives preserved — marathons still run, jobs still held, futures still imagined.
Art Sullivan was watching cartoons with his young sons when a seizure ended the ordinary afternoon and began something else entirely. Diagnosed with a grade 2 astrocytoma in late 2023, he had surgery and, four months later, ran a marathon — but the emotional reckoning of the diagnosis persisted until he understood that a treatment unavailable just a year earlier had changed his situation in ways he was still absorbing.
Josh Lehman's relationship with astrocytoma stretches back fifteen years. After remission and recurrence, he arrived at 2024 expecting the same limited options. Instead, his neuro-oncologist at Wilmot Cancer Institute offered vorasidenib — a daily pill approved by the FDA in August 2024 and the first genuinely new treatment for this cancer in decades. "The new drug has been mentally transformative," Lehman said. He still works as a human resources director at the University of Rochester, a life he credits partly to having choices he never anticipated.
Vorasidenib works by targeting the precise cellular pathway where astrocytoma grows, bypassing the blunt force of chemotherapy and radiation. For younger patients especially, this matters enormously: radiation, while effective, eventually damages memory, alters emotions, and can interfere with work and relationships for years afterward. A clinical trial of 331 patients confirmed the drug significantly extended time before recurrence and delayed the need for those harsher therapies.
Dr. Nimish Mohile, the neuro-oncologist treating both men, now manages thirty patients on vorasidenib and helped author updated national guidelines reflecting the drug's clinical evidence. He oversees care across a 27-county region larger than Vermont and New Hampshire combined — territory he describes as riddled with neuro-oncology deserts, where community physicians may encounter brain cancer only once a year and lack access to current best practices. Published guidelines and informed patients, he argues, are essential tools for closing that gap.
Vorasidenib is not a cure, and brain cancer has resisted easy solutions for reasons rooted in its rarity — too few patients to generate the data that drives breakthroughs. But the field is moving. A second new brain tumor drug, dordaviprone, received FDA approval this month. Researchers at Wilmot and four other New York institutions are investigating CAR T-cell therapy for solid tumors, and other scientists are studying how to shield brain tissue during radiation. For patients who may live twenty years or more with low-grade astrocytoma, the goal is a succession of interventions, each one pushing the hardest treatments further into the future — and for Sullivan and Lehman, that forward momentum is not an abstraction. It is the shape of hope made practical.
Art Sullivan was watching cartoons with his two young sons in December 2023 when a seizure struck without warning. An ambulance rushed him to the hospital, and after days of anxious waiting, doctors delivered the diagnosis: a grade 2 astrocytoma, a type of brain tumor that tends to strike younger adults. Surgeons removed it quickly. Four months later, Sullivan—a longtime endurance athlete—ran the Buffalo Marathon. But the emotional weight of the diagnosis lingered. What made the difference, he said, was access to a treatment that didn't exist just a year earlier.
Josh Lehman, 48, faced a different timeline. He was diagnosed with astrocytoma fifteen years ago, went into remission, and watched it return in 2024. In the past, surgery was his only option. This time, his neuro-oncologist offered something new: a daily pill called vorasidenib, approved by the FDA in August 2024. It was the first genuinely new treatment for this cancer in decades. "The new drug has been mentally transformative," Lehman said. He works as director of human resources operations at the University of Rochester and credits his care team at Wilmot Cancer Institute with giving him options he never expected to have.
Vorasidenib works by targeting the specific cellular pathway where astrocytoma grows. Unlike chemotherapy and radiation—the standard treatments for decades—the pill comes with few or no side effects for most patients, though fertility concerns exist for some. A clinical trial involving 331 patients showed the drug significantly extended the time before cancer returned and delayed the need for traditional, more toxic therapies. For younger patients especially, this matters profoundly. Radiation therapy, while effective, eventually causes cognitive damage: memory problems, emotional changes, interference with work and relationships, and in rare cases, secondary cancers years later. Anything that delays or avoids radiation in younger brains is a genuine advance.
Dr. Nimish Mohile, a neuro-oncologist at Wilmot, now has thirty patients taking vorasidenib, including both Sullivan and Lehman. In 2021, Mohile helped write the first-ever national guidelines for treating brain cancer. This year, he and the national expert panel published updated guidance in the Journal of Clinical Oncology reflecting the research behind vorasidenib's effectiveness. The drug represents a shift toward what Mohile calls "targeted therapies"—treatments designed to attack specific molecular features of a tumor rather than poisoning the entire body.
But progress in brain cancer has been glacially slow. Most treatments in use today were developed in the 1990s. The reason is simple: brain cancer is rare. When a disease affects so few people, it's difficult to gather the data needed for scientific breakthroughs and drug approvals. A typical medical oncologist might see two hundred new patients a year and encounter brain cancer in perhaps one of them. Many doctors in smaller towns and rural areas lack current knowledge of the latest surgical techniques or modern treatments. Mohile oversees care across a 27-county region in western and central New York—an area larger than Vermont and New Hampshire combined—and he describes significant "neuro-oncology deserts" where patients and providers alike lack access to cutting-edge options.
Published national guidelines help bridge this gap. When a community doctor encounters a brain cancer patient, the guidelines offer quick access to current best practices. Patient awareness matters too. "Information on new treatments empowers patients to have more understanding and to ask their doctors about all treatments," Mohile said. Sullivan's emotional recovery accelerated once he understood his options. Lehman felt fortunate simply to have a choice.
Vorasidenib is not a cure. But it represents genuine progress in a disease that has resisted easy solutions. Beyond vorasidenib, the FDA approved a second new brain tumor treatment this month: dordaviprone, which targets gliomas with a specific gene mutation. Wilmot patients participated in the clinical trials years before the drug became widely available. Researchers are also investigating CAR T-cell therapy—currently used for blood cancers—as a treatment for solid tumors including brain cancer. Wilmot recently joined four other New York research institutions to accelerate this work. Other scientists are studying how to protect brain tissue during radiation therapy, preventing damage to nerve cells as the brain attempts to rewire itself.
People with low-grade astrocytoma can live twenty years or more. The goal, Mohile said, is to have new interventions ready when they're needed, each one pushing back the moment when traditional chemotherapy and radiation become necessary. For Sullivan, still adjusting to his diagnosis but finally finding his footing, and for Lehman, facing a recurrence with unexpected hope, that forward momentum feels like everything.
Citations marquantes
The new drug has been mentally transformative.— Josh Lehman, astrocytoma patient
Whatever we can do to delay or avoid radiation therapy to the brain, especially in younger people, is a good thing.— Dr. Nimish Mohile, neuro-oncologist
Envie de l'histoire complète ?
Lire l'original sur Medical Xpress ↗
Health & Medicine